抄録
Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study.
本文言語 | 英語 |
---|---|
論文番号 | 105 |
ジャーナル | International Journal of Molecular Sciences |
巻 | 17 |
号 | 1 |
DOI | |
出版ステータス | 出版済み - 2016/01/14 |
ASJC Scopus 主題領域
- 触媒
- 分子生物学
- 分光学
- コンピュータ サイエンスの応用
- 物理化学および理論化学
- 有機化学
- 無機化学